<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43995">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533570</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-022</org_study_id>
    <nct_id>NCT02533570</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus</brief_title>
  <official_title>A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin
      in adults with active systemic lupus erythematosus (SLE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a chronic, multisystem, disabling autoimmune
      condition, which predominantly affects women of childbearing years. Treatment options for
      SLE remain relatively limited. Regardless of the specific therapy chosen, the majority of
      patients continue to require long term immunomodulatory or cytotoxic therapy, resulting in
      long-term morbidity and mortality. Brentuximab vedotin is an antibody-drug conjugate (ADC)
      consisting of: 1) the chimeric immunoglobulin (Ig) G1 antibody cAC10, specific for human
      CD30, 2) the microtubule disrupting agent monomethyl auristatin E (MMAE), and 3) a
      protease-cleavable linker that covalently attaches MMAE to cAC10. Since CD30 and/or
      CD30-expressing immune cells may play significant key roles in the pathogenesis of SLE,
      brentuximab vedotin may be an efficacious therapy. This study intends to explore the
      potential for brentuximab vedotin as a therapy for SLE.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of subjects having an Adverse Event</measure>
    <time_frame>127 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) clinical response defined by a ≥ 4 point improvement from baseline</measure>
    <time_frame>85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of Brentuximab vedotin and metabolites total antibody (TAb), and monomethyl auristatin E (MMAE)</measure>
    <time_frame>Days 1 (pre- and post-dose), 2, 3, 8, 15, 22 (pre- and post-dose), 43 (pre- and post-dose), 64 (pre- and post-dose), 85, 106 and 127 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of Brentuximab vedotin and metabolites Tab, MMAE</measure>
    <time_frame>days 1 (pre- and post-dose), 2, 3, 8, 15, 22 (pre- and post-dose), 43 (pre- and post-dose), 64 (pre- and post-dose), 85, 106 and 127 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Brentuximab vedotin and metabolites Tab, MMAE</measure>
    <time_frame>Days 1 (pre- and post-dose), 2, 3, 8, 15, 22 (pre- and post-dose), 43 (pre- and post-dose), 64 (pre- and post-dose), 85, 106 and 127 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2); of Brentuximab vedotin and metabolites Tab, MMAE</measure>
    <time_frame>Days 1 (pre- and post-dose), 2, 3, 8, 15, 22 (pre- and post-dose), 43 (pre- and post-dose), 64 (pre- and post-dose), 85, 106 and 127 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies (ATA)</measure>
    <time_frame>Days 1, 22, 43, 64, 85, 106 and 107 of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Brentuximab vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 dose groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab vedotin</intervention_name>
    <arm_group_label>Brentuximab vedotin</arm_group_label>
    <other_name>ADCETRIS (brentuximab vedotin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥ 18 years

          -  Diagnosis of SLE for at least 6 months prior to screening

          -  Active SLE as indicated by SLE Disease Activity Index (SLEDAI) ≥ 4 at screening

          -  Must have failed a treatment for SLE after a trial of at least 3 months

        Exclusion Criteria:

          -  The subject has any serious health condition, which, in the opinion of the
             Investigator, would place the subject at undue risk from the study

          -  Subject has had recent serious or ongoing infection, or risk for serious infection

          -  Subject has a history of new or recurrent malignancy within the past 5 years

          -  The subject is pregnant and/or breastfeeding

          -  The subject fulfills diagnostic criteria for another rheumatic (overlap) disease that
             may confound clinical assessments in the study

          -  The subject has urgent, severe SLE disease activity, which, in the opinion of the
             Investigator, warrants immediate immunosuppressive therapy and would not be
             appropriate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Sesterhenn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terri Lowe</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Chatham, MD</last_name>
      <phone>205-934-4212</phone>
      <email>wchatham@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Hardin, RN</last_name>
      <phone>205-934-2981</phone>
      <email>cmhardin@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Walter Chatham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020-4124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Mabaquiao, MD</last_name>
      <phone>619-334-4735</phone>
      <email>drmabaquiao@triwestresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Diana Banales</last_name>
      <phone>619-334-4764</phone>
      <phone_ext>201</phone_ext>
      <email>dbanales@triwestresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Arthur Mabaquiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research, LLC</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Ho, MD</last_name>
      <phone>562-867-8195</phone>
      <email>geraldho@advmedresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Boucher</last_name>
      <phone>657-859-0201</phone>
      <email>michb1966@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Striebich, MD</last_name>
      <phone>303-724-7607</phone>
      <email>christopher.striebich@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Grosskreuz, MD</last_name>
      <phone>303-724-7518</phone>
      <email>Ruth.Grosskreuz@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Striebich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida - Corporate</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Levin, MD</last_name>
      <phone>727-466-0078</phone>
      <email>rlevin@crwf.com</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Gray, ARNP</last_name>
      <phone>727-466-0078</phone>
      <phone_ext>230</phone_ext>
      <email>MGray@crwf.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakes Research, LLC</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedicto Fernandez, MD</last_name>
      <phone>786-362-5763</phone>
      <email>drfernandez@lakesresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Yamile Sanchez</last_name>
      <phone>786-362-5763</phone>
      <email>ysanchez@lakesresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benedicto Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Poiley, MD</last_name>
      <phone>407-271-8030</phone>
      <email>jeffreypoiley@earthlink.net</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Cortese</last_name>
      <phone>407-271-8030</phone>
      <email>dcortese@omegarcllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Poiley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McIlwain Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harris McIlwain, MD</last_name>
      <phone>813-345-2380</phone>
      <email>harris.mcilwain@mmghealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pifer</last_name>
      <phone>813-345-2391</phone>
      <email>gretchen.pifer@mmghealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Harris McIlwain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Maksimowicz-McKinnon, MD</last_name>
      <phone>313-916-2631</phone>
      <email>kmckinn2@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Jenna Hudy</last_name>
      <phone>313-916-9328</phone>
      <email>jhudy1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Maksimowicz-McKinnon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clayton Medical Associates, P.C.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Budd, MD</last_name>
      <phone>314-646-0688</phone>
      <email>jbudd@claytonmed.com</email>
    </contact>
    <contact_backup>
      <last_name>Laci Hueffmeier, MA, CCRC</last_name>
      <phone>314-646-0688</phone>
      <email>lhueffmeier@claytonmed.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Budd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Physicians at Brooklyn Heights</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Goddard, MD</last_name>
      <phone>646-962-4650</phone>
      <email>studycoordinatorgoddard@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Debra London</last_name>
      <phone>646-962-4681</phone>
      <email>studycoordinatorgoddard@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Goddard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Jane Box, MD</last_name>
      <phone>704-247-9179</phone>
      <email>janebox@boxarthritis.com</email>
    </contact>
    <contact_backup>
      <last_name>Joe Howe, CRC</last_name>
      <phone>704-247-9179</phone>
      <phone_ext>201</phone_ext>
      <email>joe.howe@djlresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Emily Jane Box, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatology Center of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Khan, MD</last_name>
      <phone>405-606-8730</phone>
      <email>mfkhan@oklahomaarthritis.com</email>
    </contact>
    <contact_backup>
      <last_name>Cheyenne Collins</last_name>
      <phone>405-606-8730</phone>
      <email>collinsc@oklahomaarthritis.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammad Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramesh C Gupta MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramesh Gupta, MD</last_name>
      <phone>901-681-9670</phone>
      <email>rcgupta42001@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Candence Wilson</last_name>
      <phone>9016819670</phone>
      <email>guptasra28@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ramesh Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Pickrell, MD</last_name>
      <phone>512-388-5717</phone>
      <email>ppickrell@tektonresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Marianna Alesi</last_name>
      <phone>512-388-5717</phone>
      <email>malesi@tektonresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Pickrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Waller, MD</last_name>
      <phone>281-481-8557</phone>
      <email>pwallermd@accurateclinicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeremy Longoria</last_name>
      <phone>281-481-8557</phone>
      <email>jlongoria@accurateclinicalresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Philip Waller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic of Northern Virginia, PC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205-3606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Kempf, MD</last_name>
      <phone>703-525-3069</phone>
      <email>pwkempf@rheum4u.com</email>
    </contact>
    <contact_backup>
      <last_name>Charlene Henderson, RN, BSN</last_name>
      <phone>703-300-5483</phone>
      <email>chenderson@rheum4u.com</email>
    </contact_backup>
    <investigator>
      <last_name>Phillip Kempf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>July 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
